- MGNX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $16.2 million.
- MGNX has traded 435,172 shares today.
- MGNX is down 12.1% today.
- MGNX was up 11.7% yesterday.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in MGNX with the Ticky from Trade-Ideas. See the FREE profile for MGNX NOW at Trade-Ideas More details on MGNX: MacroGenics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. Currently there are 6 analysts that rate Macrogenics a buy, no analysts rate it a sell, and none rate it a hold. The average volume for Macrogenics has been 244,500 shares per day over the past 30 days. Macrogenics has a market cap of $940.3 million and is part of the health care sector and drugs industry. Shares are up 23.3% year-to-date as of the close of trading on Friday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Macrogenics as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share and deteriorating net income.